XOMA Refinances Royalty-Based Loan Facility for $55 Million

Date: 06/13/08

Cahill represented XOMA (US) LLC., a leader in the discovery and development of antibody therapeutics, as borrower in an amended loan facility under which it has borrowed $55 million from Goldman Sachs Specialty Lending Group, L.P. The loan is secured by the royalty revenues the company receives from sales of RAPTIVA®, LUCENTIS® and CIMZIA®. The company used the proceeds of the new loan in part to repay the remaining $22.1 million of principal outstanding under its existing loan from Goldman Sachs.

Related Attorneys: Geoffrey E. Liebmann, Justin Breen, Adam D. Summers

Related Practice: Corporate